Ventyx Biosciences, Inc. (VTYX) Dividend History

Company News

• Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

  Ventyx Biosciences has initiated a Phase 2a trial of its NLRP3 inhibitor VTX3232 in patients with early Parkinson's disease. The trial aims to evaluate the safety, tolerability, and impact of VTX3232 on disease-relevant biomarkers and microglial activation.

  GlobeNewswire Inc.
• Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

  SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:

  GlobeNewswire Inc.
• Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

  SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.

  GlobeNewswire Inc.
• What Makes Ventyx Biosciences (VTYX) a New Buy Stock

  Ventyx Biosciences (VTYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  Zacks Investment Research
• Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session

  U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday. Shares of Kura Sushi USA, Inc. (NASDAQ: KRUS) climbed 6% to $110.11 in pre-market trading following the release of second-quarter results. The company reported quarterly losses of 9 cents per share, missing the analyst estimate of losses of 3 cents per share. Quarterly sales came in at $57.29 million, beating the $56.64 million analyst consensus estimate, according to data from Benzinga Pro. Kura Sushi shares climbed 6% to $110.11 in pre-market trading. Here ...

  Benzinga

  Featured Companies: CNK CRBU DNUT FAAS FRGE IVVD KRUS